Tubulis

(IN BRIEF) Tubulis has been named one of 2024’s “Fierce 15” biotechnology companies by Fierce Biotech. This recognition celebrates Tubulis’ innovative work in ADC development and its commitment to improving cancer treatment outcomes. With significant recent advancements, including a €128 … Read the full press release →

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release →